您的位置:医药网首页 > 医药资讯 > 医药新闻 > 最新爆料!武田将支付$22亿和解糖尿病药物艾可拓(Actos)致癌风波

最新爆料!武田将支付$22亿和解糖尿病药物艾可拓(Actos)致癌风波


2015年4月1日讯/生物谷BIOON/--上周,日本制药巨头武田(Takeda)在糖尿病市场投下了一枚重磅炸弹,该公司研发的全球首个每周口服一次的降糖药Zafatek(trelagliptinsuccinate,曲格列汀琥珀酸盐)获批,给广大2型糖尿病患者群体带来了福音。然而不幸的是,同样在糖尿病市场,武田目前正深陷于另一种糖尿病畅销药艾可拓(Actos)的致癌风波。(相关阅读:糖尿病重磅消息!全球首个每周一次口服降糖药Zafatek获批!)
本周一彭博社最新报道,据3位知情人士爆料,武田将支付超过22亿美元,用于解决因隐瞒旗下糖尿病药物艾可拓(Actos,通用名:吡格列酮)致癌风险的相关指控。据爆料,武田此次将解决在美国联邦及州立法院超过8000例法律诉讼,每个案子将支付27.5万美元,合计支付金额超过22亿美元,这也将是美国制药历史上最大的罚单之一。
知情人士透露,武田提供的解决方案是,只有那些已经提起诉讼或已经聘请律师即将提交诉讼的服用过Actos的糖尿病患者才有资格参与赔偿,这一限制条件意图帮助该公司避免支付新一波的法律诉讼。该人士透露,目前武田与联邦及州立法院尚未达成最终协议,仍有谈判失败的可能性;武田也可能选择解决其中一些诉讼,并继续在其他诉讼上进行协商。不过,也有一些律师表达了强烈的反对,认为22亿美元的赔偿金不足以支付所有已患膀胱癌的糖尿病患者。
据了解,自2013年以来,武田被指控至少在9个临床试验中隐瞒Actos的致癌风险。去年,美国联邦法院陪审团对武田及合作伙伴礼来分别处于60亿美元和30亿美元(合并90亿美元)的罚款,成为美国制药领域的最大一笔罚单。不过去年10月,这一罚单被戏剧性地降至3680万美元,降低幅度高达99%。而就在业界认为武田和礼来会松一口气,结束这场惊心动魄的诉讼攻守战时,武田和礼来的律师却表示:还要再次上诉!
武田与合作伙伴礼来自1999年开始在美国联合销售糖尿病药物艾可拓(Actos),直至2006年结束合作。之后,礼来保留Actos在亚洲及欧洲一些国家、加拿大、墨西哥的销售权。根据彭博社汇总的数据,艾可拓(Actos)在截止2011年3月的年销售额峰值高达45亿美元,约占武田当时收入的27%。另外,根据法庭文件,艾可拓(Actos)自1999年上市以来,合计销售额已超过160亿美元。目前,该药正面临着来自兰伯西(Ranbaxy)的仿制药的竞争。
英文原文:TakedaOffers$2.2BilliontoSettleActosDrugCases
(Bloomberg)--TakedaPharmaceuticalCo.hasofferedtopaymorethan$2.2billiontoresolveclaimsofhidingitsActosdiabetesmedicine’scancerrisksinwhatwouldbeoneofthelargestU.S.settlementsofpatientlawsuitstargetingdrugsordevices,threepeoplefamiliarwiththemattersaid.
OfficialsatAsia’slargestdrugmakerproposetosettlemorethan8,000lawsuitsinfederalandstatecourtsintheU.S.,saidthepeople,whoaskednottobeidentifiedbecausetheyweren’tauthorizedtospeakpubliclyabouttheoffer.
Suchadealwouldamounttoapaymentofabout$275,000foreachcase.Anysettlementwouldbethefirstinthethree-yearlitigationoverthediabetesdrug.
AfederaljuryinLouisianalastyearorderedTakedaandEliLilly&Co.topayacombined$9billionindamagestoashopkeeperwhoblamedActosforcausinghisbladdercancer.Thataward,theseventh-largestinU.S.historybasedondatacompiledbyBloomberg,waslaterreducedbymorethan99percentto$36.8millionbyajudge.
“ThisisastrongsignalthatTakedareallywantstosettlethesecasessoitcanavoidanymorehugeverdicts,”CarlTobias,whoteachesproduct-liabilitylawattheUniversityofRichmondinVirginia.“Buttheper-casenumberindicatestheydon’twanttohavetopayapremiumtosettletheseclaims.”
TeaganKnapp,anoutsidespokeswomanforOsaka,Japan-basedTakeda,didn’timmediatelyrespondtophoneande-mailmessagesafterregularbusinesshoursTuesdayseekingcommentonthesettlementofferintheActoslitigation.KazumiKobayashi,aTakedaspokesmaninTokyo,wasn’timmediatelyabletorespondtoarequestforcomment.
ProposalCritics
Afinaldealhasn’tbeenreachedandthetalkscouldstillfallapart,thepeoplesaid.Takedaalsocouldchoosetosettlesomelawyers’inventoriesofcasesunderthe$2.2billionproposalandcontinuenegotiationsonothers,thepeopleadded.
MorefromBloomberg.com:IndiaSensexSwingsBeforeHolidaysAfterWorstMonthin2Years
There’soppositiontoTakeda’ssettlementofferfromsomelawyerswhohavesuedthedrugmakeroverActos,thepeoplefamiliarwithitsaid.Someattorneyscontend$2.2billionisn’tenoughcompensationforallpatientswhodevelopedbladdercanceraftertakingthedrug,thepeoplesaid.
ActossalespeakedintheyearendedMarch2011at$4.5billionandaccountedfor27percentofTakeda’srevenueatthetime,accordingtodatacompiledbyBloomberg.Actoshasgeneratedmorethan$16billioninsalessinceits1999release,accordingtocourtfilings.TakedanowfacesgenericcompetitionoverthedrugfromRanbaxyLaboratoriesLtd.
ConsolidatedLawsuits
Morethan3,500ActossuitshavebeenconsolidatedbeforeU.S.DistrictJudgeRebeccaDohertyinLafayette,Louisiana,forpretrialinformationexchanges,accordingtocourtdockets.Thecompanyfacesanother4,500casesinstatecourtsinIllinois,WestVirginia,CaliforniaandPennsylvania,accordingtocourtrecords.
UnderTakeda’soffer,onlyActospatientswhohavealreadysuedorwhohavealreadyhiredalawyertofilealawsuitwouldbeeligibletoparticipateinthesettlement,thepeoplesaid.Thatlimitationisdesignedtohelpthecompanyavoidpayingtoresolveanewwaveofsuits,thepeopleadded.
“Thereisnodealanditishighlyquestionablewhethertherewillbeonewithoutfurtherscorched-earthlitigation,”PaulPennock,oneoftwolawyersoverseeingthefederal-courtlitigationforplaintiffs,saidinane-mail“ButatleastTakedarecognizesthatattemptingtocompensatethesecancervictimsandtheirfamiliesistherightthingtodo.”
Takeda’sLawyer
TakedahiredDouglasMarvin,alawyerwithWilliams&ConnollyLLPinWashington,tohelpnegotiatethepotentialdealwithlawyersforformerActospatients,thepeoplesaid.Marvinhelpednegotiatea$4.85billionsettlementwithMercktoresolveabout30,000lawsuitsoveritswithdrawnpainkillerVioxxin2007.
Marvindidn’treturnacallseekingcommentafterregularbusinesshoursTuesday.
Takedahasfacedatleastninetrialssince2013overclaimsithidActos’scancerrisks,includingtheLouisianatrial.Thecompanyhaswonthreedefenseverdictsandotherdamageawardsagainstthedrugmakerhavebeenthrownoutorareonappeal.
Still,fivejuriesthathavereviewedtheevidenceofTakeda’shandingofActoshaveheldthecompanyliableforconsumers’injuries.
PotentialJudgments
“IfTakedacansettlethemultidistrictcasesfor$2.2billion,theyshouldsignthepapersandleavetown,”ErikGordonaprofessorattheUniversityofMichigan’sbusinessandlawschoolswhoteachesaboutclass-actionsettlements.
“Giventheresultsofthetrialssofarandthenumberofpotentialjudgmentsagainstthecompany,$2.2.billionisabargain,”Gordonadded.
FormerActosusersarguedTakedaexecutivesignoredordownplayedconcernsaboutthedrug’scancer-causingpotentialbeforeitwentonsaleintheU.S.in1999andmisledU.S.regulatorsaboutthemedicine’srisks.
LillywasTakeda’sU.S.partnerinsellingandmarketingthedrugoversevenyearsstartingin1999.Thatpartnershipendedin2006,withLillyretainingrightstosellActosinpartsofAsiaandEurope,aswellasinCanadaandMexico.
LillyofficialscontendTakedaagreedtocoveralllegalcostsstemmingfromitsU.S.salesofActosandforalltheLouisianaverdict.
Takeda’ssettlementofferismorethandoublewhatStrykerCorp.agreedtopaylastyeartoresolveclaimsoveritsrecalledartificialhipsandmorethantriplethe$650millionGermandrugmakerBoehringerIngelheimGmbHpaidtosettlelawsuitsoveritsPradaxablood-thinningdrug.
TheconsolidatedActoscasesinLouisianaareInReActos(Pioglitazone)ProductsLiabilityLitigation,11-md-02299,U.S.DistrictCourt,WesternDistrictofLouisiana(Lafayette).
医药网新闻
返回顶部】【打印】【关闭
扫描100医药网微信二维码
视频新闻
图片新闻
医药网免责声明:
  • 本公司对医药网上刊登之所有信息不声明或保证其内容之正确性或可靠性;您于此接受并承认信赖任何信息所生之风险应自行承担。本公司,有权但无此义务,改善或更正所刊登信息任何部分之错误或疏失。
  • 凡本网注明"来源:XXX(非医药网)"的作品,均转载自其它媒体,转载目的在于传递更多信息,并不代表本网赞同其观点和对其真实性负责。本网转载其他媒体之稿件,意在为公众提供免费服务。如稿件版权单位或个人不想在本网发布,可与本网联系,本网视情况可立即将其撤除。联系QQ:896150040